通脉养心丸联合普罗帕酮治疗室性期前收缩的临床疗效观察

Clinical observation of Tongmai Yangxin pills combined with Propafenone in treatment of ventricular premature beat

目的观察通脉养心丸联合普罗帕酮治疗室性期前收缩的临床疗效和安全性。方法将符合诊断标准的96例室性期前收缩患者按随机数字表法随机分为治疗组和对照组,每组48例。对照组在常规治疗基础上加用普罗帕酮治疗,治疗组在常规治疗基础上加用通脉养心丸联合普罗帕酮治疗,两组疗程均为4周,比较两组临床疗效及不良反应发生率。结果24 h动态心电图临床总有效率治疗组为92%对照组为75%,两组比较差异有统计学意义(P<0.05);临床症状改善总有效率治疗组为94%,对照组为69%,两组比较,差异有显著统计学意义(P<0.01),两组不良反应发生率均较轻微。结论通脉养心丸联合普罗帕酮治疗室性期前收缩疗效确切,安全性高。

Objective To observe the clinically therapeutic effect of Tongmai Yangxin pills combined with Propafenone on ventricular premature beat and its safety. Methods A total of 96 patients were randomly divided into trial group and control group （ n = 48/group）. On the base of therapy toward protopathy, the control group was treated with Propafenone, and the trial group was additionally treated with Tongmai Yangxin pills. The therapy lasted for 4 weeks. Clinical effect and incidence rate of adverse reaction were compared between the two groups. Results According to 24-h dynamic eletrocardiography （holter） , total effective rate was 92% in the trial group and 75% in the control group, between which there was a statistically significant difference （P 〈 0.05 ）. The rate of improvement in clinical symptoms of the trial group was 94% , better than that （69%） of the control group （P 〈0.01 ）. The incidence rate of adverse reaction was very low in both the two groups. Conclusion Tongmai Yangxin pills combined with Propafenone is safe and therapeutically effective on ventricular premature beat.